Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | MDH1 | P40925 | 1/20 | 0.46 |
| ▸ | MDH2 | P40926 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668221 | 0.84 | MAPT (0.59) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL14648692 | 0.84 | KDM4E (0.50) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL666907 | 0.84 | CYP2B6 (0.60) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL6385807 | 0.84 | TTR (0.47) | TTRCYP2B6PDE4BCA12CA1 | |
| SCHEMBL21955097 | 0.83 | MDH1 (0.46) | MDH1MDH2CYP2B6NOTUMPDE4B | |
| SCHEMBL5763287 | 0.83 | CYP2B6 (0.53) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL27001789 | 0.83 | MAPT (0.49) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL31747453 | 0.80 | CYP2B6 (0.53) | MDH1MDH2CYP2B6PDE4BMAPT | |
| SCHEMBL13535957 | 0.79 | TTR (0.59) | TTRNOTUMMAPTCA12CA1 | |
| SCHEMBL17346492 | 0.79 | TSHR (0.43) | MDH1MDH2CYP2B6PDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0975618-B1 | a new process for the preparation of 3-N,N-dicycobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | EP | disclosed |
| US-6197978-B1 | ESTERIFICATION, PROPARYLATION, HEATING, HYDROLYSIS, ETHERIFICATION, REDUCTION, ALKYLATION, CYCLIZATION, AMINATION | ASTRA AKTIEBOLAG (SE) | 2001-03-06 | — | — | US | disclosed |
| EP-0975618-A1 | A NEW PROCESS | Astra Aktiebolag (SE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046586-A1 | A NEW PROCESS | ASTRA AKTIEBOLAG (SE) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | TTR 160/4885MDH1 1644/4885MDH2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.